Nasdaq

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
Cure Today

Keytruda Regimen May Improve Event-Free Survival in Head and Neck Squamous Cell Carcinoma

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...
Cure Today

FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer

Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 trial showed a ...
Nasdaq

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients ...

KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American ...
MedPage Today

New Standard of Care in Locally Advanced Head and Neck Cancer

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) prolonged event-free survival (EFS), the ...
The American Journal of Managed Care

Ravindra Uppaluri, MD, PhD

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world ...